Liminatus Pharma Inc. Ordinary Shares LIMN 深 沪
已收盘 08-01 16:00:00 美东时间
5.93
-0.340
-5.42%
华盛通- 最 高6.28
- 今 开6.05
- 成交量 17.34万股
- 最 低 5.85
- 昨 收 6.27
- 总市值 1.54亿
- 52周最高 33.66
- 市盈率 静 --
- 换手率 0.67%
- 52周最低 4.40
- 委 比 -16.23%
- 总股本 2601.46万
- 历史最高 33.66
- 量 比 0.32
- 振 幅 6.86%
- 历史最低 4.40
- 每 手 1
- 风险率 5.90%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股医疗公司Liminatus Pharma大涨超5%！拟筹募5亿美元资金全力投资BNB
Liminatus Pharma宣布计划成立子公司「American BNB Strategy」专注于投资BNB。
07-28 12:33
美股醫療公司Liminatus Pharma大漲超5%！擬籌募5億美元資金投資BNB
Liminatus Pharma宣佈計劃成立子公司「American BNB Strategy」專注於投資BNB。
07-28 12:31
Liminatus Pharma Surges Over 5% After Announcing $500M BNB Investment Strategy
On Monday, July 28, Nasdaq-listed Liminatus Pharma Inc. (LIMN) jumped 5.28% in pre-market trading after unveiling plans to launch a dedicated crypto subsidiary focused on Binance Coin (BNB).
07-28 12:29
Liminatus Pharma Inc. to Launch “American BNB Strategy” Subsidiary and Target Up To $500 Million Fund for BNB Investment as Part of Crypto Market Initiative
Liminatus Pharma plans to expand into the cryptocurrency sector by investing up to $500 million in BNB Coin through a new subsidiary, "American BNB Strategy." The company aims to hold BNB for long-term strategic value, emphasizing the ecosystem's growth potential. CEO Chris Kim highlighted BNB's technology, global user base, and ecosystem expansion as key factors. The initiative, which is still subject to regulatory approval, reflects Liminatus' ...
07-28 11:30
美股牛股 | 计划长期储备比特币，MFH飙涨超50%；公司获高额溢价收购，CIO大涨超24%
计划长期储备比特币，MFH飙涨超50%；公司获高额溢价收购，CIO大涨超24%；与甲骨文达成供电合作，BE大涨23%>>
07-25 19:50
Liminatus Pharma Inc. Evaluates Formation of Digital Asset Investment Vehicle Targeting Up To $500 Million in Capital Strategies
Liminatus Pharma announced the initiation of a strategic review to explore forming a digital asset investment subsidiary for treasury diversification. The subsidiary, if approved, would focus on digital asset allocation and operate independently of the company's core clinical pipeline. The company is evaluating up to $500 million in potential capital formation through various financing tools while ensuring compliance with SEC regulations. No capi...
07-25 12:31
Liminatus Pharma Inc. Takes Next Step in Evaluating Digital Asset-Linked Capital Strategy
Liminatus Pharma has partnered with Digital Offering LLC as its exclusive placement agent to explore strategic capital raises, potentially involving digital asset strategies and exempt financing structures like convertible debentures or equity-linked securities. This collaboration aims to strengthen Liminatus's capital structure while advancing its cancer immunotherapy research. No financing transaction is finalized, and any potential deal remain...
07-24 12:31
Liminatus Pharma Initiates Strategic Review To Evaluate Potential Inclusion Of Regulated Digital Asset Strategies As Part Of Broader Treasury Management Framework
Liminatus Pharma, Inc. (NASDAQ:LIMN), a preclinical-stage biopharmaceutical company dedicated to the development of targeted cancer immunotherapies, today announced that it has initiated a strategic review to evaluate
07-23 01:31
Liminatus Pharma, Inc. Initiates Strategic Review of Blockchain-Integrated Treasury Strategy
<p><p><em>Preclinical-stage biotech company explores digital asset treasury opportunities to enhance capital efficiency while maintaining core focus on immunotherapy innovation</em></p> <p align="justify">Liminatus Pharma, Inc., a preclinical-stage biopharmaceutical company focused on developing targeted cancer immunotherapies, has initiated a strategic review to evaluate the potential inclusion of regulated digital asset strategies within its tr...
07-22 17:30
Liminatus Pharma Settles with Alta Partners, Issues Shares
Liminatus Pharma ( ($LIMN) ) has provided an announcement. On July 16, 2025, Li...
07-18 04:52
